TORONTO, Nov. 06, 2025 (GLOBE NEWSWIRE) — McEwen Inc. (NYSE/TSX: MUX) today announced its third quarter (Q3) and year-to-date (9M) results for the period ended September 30, 2025, and reported on its plan to double production by 2030, lower costs, and extend mine life across all operations. Management believes these initiatives provide an achievable path toward our goal of 250,000 to 300,000 GEOs Consolidated Annual Production by 2030. McEwen is advancing the following projects: The Fox Complex (Stock and Grey Fox) is expected to contribute approximately 50% of the total production goal. This will be followed by the Gold Bar Mine Complex (Gold Bar Mine, Windfall and Lookout Mountain) at 30%, and El Gallo (Phases 1 and 2) at 20%. The acquisition of Canadian Gold Corp’s Tartan mine is excluded from this forecast.Stock Mine...

Highlights Shauna McIntyre appointed new CEO of Ensurge Micropower ASA.  New Board of Directors, including the election of Alex Munch-Thore as new Chairman of the Board.  Signed Joint Development Agreement with Corning, a Fortune 500 industry-leading innovator in glass, ceramics, and materials science.  Signed Investment Agreement with Corning, benefiting from full-time Corning resources on-site at Ensurge to support ongoing development of ultra-high performance product line extension using Corning’s Ribbon Ceramic substrate.  Successfully shipped numerous battery prototypes as fulfillment toward evaluation agreements  Improved manufacturing throughput, quality and repeatability including roll-to-roll (R2R) cell layer manufacturing and battery cell assembly.  Progressing multi-year paid development programs across medical and consumer...

YORK, Pa., Nov. 06, 2025 (GLOBE NEWSWIRE) — The York Water Company’s (NASDAQ:YORW) President, JT Hand, announced the Company’s financial results for the third quarter and the first nine months of 2025. President Hand reported that third quarter operating revenues of $20,361,000 increased $646,000 and net income of $6,201,000 increased $338,000 compared to the third quarter of 2024. Basic and Diluted Earnings per share of $0.43 for the three-month period increased $0.02 compared to the same period last year. Increased revenues were primarily due to growth in the customer base and revenues from the Distribution System Improvement Charge (DSIC). The DSIC is a Pennsylvania Public Utility Commission allowed charge that water utilities collect from customers for the replacement of aging infrastructure.   Income taxes decreased...

– American Place Casino Continued Its Strong Growth, With Revenues Increasing 14.0% to a New Property Record in the Third Quarter of 2025 – Consolidated Operating Income Rose 40.3% to $3.4 Million in the Third Quarter of 2025; Net Loss Improved to $(7.7) Million from $(8.5) Million – Adjusted EBITDA Increased 26.1% to $14.8 Million in the Third Quarter of 2025, Reflecting Strong Results at American Place and a $2.1 Million Contribution from Chamonix/Bronco Billy’s LAS VEGAS, Nov. 06, 2025 (GLOBE NEWSWIRE) — Full House Resorts, Inc. (Nasdaq: FLL) today announced results for the third quarter ended September 30, 2025. On a consolidated basis, revenues in the third quarter of 2025 were $78.0 million, an increase from $75.7 million in the prior-year period. These results reflect the continued ramp-up of operations...

DALLAS, Nov. 06, 2025 (GLOBE NEWSWIRE) — RAVE Restaurant Group, Inc. (NASDAQ: RAVE) today reported financial results for the first quarter of fiscal 2026 ended September 28, 2025. First Quarter Highlights:The Company recorded net income of $0.6 million for the first quarter of fiscal 2026, a 22.6% increase from the same period of the prior year. Income before taxes increased by 22.4% to $0.9 million for the first quarter of fiscal 2026 compared to the same period of the prior year. Total revenue increased by $0.1 million to $3.2 million for the first quarter of fiscal 2026 compared to the same period of the prior year, a 5.3% increase. Adjusted EBITDA increased by $0.1 million to $0.8 million for the first quarter of fiscal 2026 compared to the same period of the prior year, a 15.3% increase. On a fully diluted basis, net income...

Submitted a New Drug Application (NDA) for accelerated approval of bitopertin in erythropoietic protoporphyria (EPP) on September 29, 2025; Awarded the FDA Commissioner’s National Priority Voucher (CNPV), which is designed to shorten the expected NDA review period to 1-2 months from NDA acceptanceAcceleration of ongoing efforts to support the potential earlier approval and commercialization of bitopertin for EPP in the US, expected in late 2025 or early 2026 Initial data from Phase 2 study of DISC-0974 in patients with anemia of myelofibrosis (MF) to be presented at the American Society of Hematology (ASH) conference in December Progressing ongoing Phase 2 study of DISC-3405 in polycythemia vera (PV) and initiated a Phase 1b study of DISC-3405 in sickle cell disease (SCD) in October Strong financial position ending Q3 with approximately...

– Private Placement Financing of Up to $105.3 Million Closed in October 2025 to Fund Operations and R&D – Sally Lawlor Appointed CFO to Support Commercialization and Financial Operations – Orphan Drug Designation Awarded by FDA to QRX003 for Netherton Syndrome  – Pediatric Netherton Clinical Program Expanded Based on Positive Long-Term Safety and Efficacy Data – QRX003 Pivotal Studies to Commence Enrollment in Q4 2025 – NETHERTON NOW Awareness Campaign Videos Achieve Over 1.5 Million Views in 6 Months Since Launch. – Positive Peeling Skin Data and Study Expansion Plans Released ASHBURN, Va., Nov. 06, 2025 (GLOBE NEWSWIRE) — Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (“Quoin” or the “Company”), a late clinical-stage specialty pharmaceutical company focused on rare and orphan diseases provided a corporate...

SOUTH SAN FRANCISCO, Calif., Nov. 06, 2025 (GLOBE NEWSWIRE) — Aligos Therapeutics, Inc. (Nasdaq: ALGS, “Aligos”), a clinical stage biotechnology company focused on improving patient outcomes through best-in-class therapies for liver and viral diseases, today reported recent business progress and financial results for the third quarter 2025. “Our Phase 2 B-SUPREME study of pevifoscorvir sodium (pevy) is enrolling nicely, with subjects dosed across a number of countries, including the U.S., China, Hong Kong, and Canada,” stated Lawrence Blatt, Ph.D., M.B.A., Chairman, President, and Chief Executive Officer of Aligos Therapeutics. “We are pleased with the progress to date and look forward to interim readouts in 2026. Importantly, we look forward to sharing additional pevy data next week at AASLD’s The Liver Meeting®. We maintain our...

– Enrollment to date of 100 patients, with 80 patients completing treatment in the ongoing Halneuron® Phase 2b trial, prespecified interim analysis remains on track for Q4 2025 release – – Secured exclusive worldwide, royalty free license to develop and commercialize SP16 as a synergistic and complementary pipeline treatment for cancer-related pain in an all-stock transaction –   ATLANTA, Nov. 06, 2025 (GLOBE NEWSWIRE) — Dogwood Therapeutics, Inc. (Nasdaq: DWTX) (the “Company”), a development-stage biotechnology company developing new medicines to treat pain and neuropathy, today announced financial results for the third quarter ended September 30, 2025. “The Company continues to execute at a high level, including recruitment of 100 patients in our ongoing Halneuron® Phase 2b trial and the addition of a,...

MACAU, Nov. 06, 2025 (GLOBE NEWSWIRE) — Melco Resorts & Entertainment Limited (Nasdaq: MLCO) (“Melco” or the “Company”), a developer, owner, and operator of integrated resort facilities in Asia and Europe, today reported its unaudited financial results for the third quarter of 2025. Total operating revenues for the third quarter of 2025 were US$1.31 billion, representing an increase of approximately 11% from US$1.18 billion for the comparable period in 2024. The increase in total operating revenues was primarily attributable to the improved performance in both overall gaming and non-gaming operations. Operating income for the third quarter of 2025 was US$184.5 million, compared with US$138.6 million in the third quarter of 2024. Melco’s Adjusted Property EBITDA(1) was US$380.4 million in the third quarter of 2025, compared...